These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 3114883)

  • 21. Thrombolytic therapy and equivalence trials.
    White HD
    J Am Coll Cardiol; 1998 Mar; 31(3):494-6. PubMed ID: 9502625
    [No Abstract]   [Full Text] [Related]  

  • 22. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombolytic therapy.
    Collen D; Lijnen HR
    Ann N Y Acad Sci; 1991; 614():259-69. PubMed ID: 1902640
    [No Abstract]   [Full Text] [Related]  

  • 24. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
    Sherry S
    Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
    [No Abstract]   [Full Text] [Related]  

  • 25. [Plasminogen activators as thrombolytic agents in myocardial infarction].
    Chamone DA; Massumoto C; Fujimura AY; Pileggi F; Bellotti G
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(6):288-94. PubMed ID: 2518605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
    Gurewich V
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New thrombolytic drugs in acute myocardial infarction: theoretical and practical considerations.
    Verstraete M
    Circulation; 1987 Aug; 76(2 Pt 2):II31-8. PubMed ID: 3111745
    [No Abstract]   [Full Text] [Related]  

  • 28. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
    Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
    Yokoyama M; Ichikawa Y; Yatani A; Matsui K; Nakahara H; Kaneko M; Sakurama T; Ueshima S; Matsuo O
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):571-5. PubMed ID: 8891884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient renaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in Escherichia coli as inclusion bodies.
    Orsini G; Brandazza A; Sarmientos P; Molinari A; Lansen J; Cauet G
    Eur J Biochem; 1991 Feb; 195(3):691-7. PubMed ID: 1847867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The acyl-enzymes and pro-urokinase: promising new thrombolytic agents.
    Samama M; Horellou MH; Nguyen G; Conard J
    Haemostasis; 1986; 16 Suppl 3():33-7. PubMed ID: 3095196
    [No Abstract]   [Full Text] [Related]  

  • 33. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCI for totally occluded site consisting of huge thrombus.
    Oyama N; Urasawa K; Sakai H; Kitabatake A
    J Invasive Cardiol; 2003 Oct; 15(10):603-6. PubMed ID: 14519898
    [No Abstract]   [Full Text] [Related]  

  • 36. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
    Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
    Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
    [No Abstract]   [Full Text] [Related]  

  • 37. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
    Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mode of action and pharmacology of saruplase.
    Vermeer F
    Int J Clin Pract Suppl; 1998 Nov; 99():6-8. PubMed ID: 10344034
    [No Abstract]   [Full Text] [Related]  

  • 39. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.